FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington,	D.C.	20049	

STATEMENT OF	CHANGES IN	BENEFICIAL	OWNERSHI

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ege David S.						2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]							(Che	ck all app Direc	onship of Reportin Il applicable) Director Officer (give title		son(s) to Is 10% Ov	wner	
	(Fii RES THERA	APEUTICS, INC	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 10/27/2022						,	See Remarks				.,,		
(Street)	IDGE M.	A 0.	2139 Zip)		4. If <i>i</i>								Line)	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	icial	ly Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		4 and Securiti		ties Form cially (D) (I I Following (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)							
						Code	v	Amount	(A) (D)	or P	rice	Transa	nsaction(s) tr. 3 and 4)			(111501. 4)			
Common stock 10/27/2				2022		A ⁽¹⁾		20,000	A	. ;	60.00	51	1,746		D				
Common	stock			10/31/2	:022		S ⁽²⁾		5,012	Γ) (57.93	40	46,734		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction Date Execution Date, if any or Exercise (Month/Day/Year)		4. Transa Code (8)	ction of		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		etr.	. Price of erivative ecurity nstr. 5)	ve derivative Securities	Ownersh Form: Direct (D) or Indirec (I) (Instr.	Ownership Form:	Beneficial Ownership t (Instr. 4)				
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er					

Explanation of Responses:

- 1. On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vest in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On October 27, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Remarks:

Executive Vice President and Chief Technology Officer

/s/ Thomas J. DesRosier, attorney-in-fact for David S. 10/31/2022 Ege

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.